264905-39-7

Basic information

• Product Name: 1-Boc-4-Ethylaminopiperidine
• Synonyms: 4-ETHYLAMINO-1-BOC-PIPERIDINE;4-ETHYLAMINO-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;BUTTPARK 90\06-13;1-Boc-4-Ethylaminopiperidine;4-Ethylamino-1-Boc;tert-butyl 4-(ethylamino)piperidine-1-carboxylate;tert-butyl 4-(ethylamino)piperidine-1-carboxylate hydrochloride;N-Boc- 4-(ethylaMino)piperidine-HCl
• CAS NO: 264905-39-7
• Molecular Formula: C₁₂H₂₄N₂O₂
• Molecular Weight: 228.33
• Mol File: 264905-39-7.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 306.062 °C at 760 mmHg
• Flash Point: 138.902 °C
• Appearance: /
• Density: 1.007 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.485
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.25±0.20(Predicted)
• CAS DataBase Reference: 1-Boc-4-Ethylaminopiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-Ethylaminopiperidine(264905-39-7)
• EPA Substance Registry System: 1-Boc-4-Ethylaminopiperidine(264905-39-7)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36
• Hazardous Substances Data: 264905-39-7(Hazardous Substances Data)

Usage

General Description

1-Boc-4-Ethylaminopiperidine is a chemical compound with the molecular formula C14H28N2O2. It is a white to off-white solid that is commonly used in organic synthesis and medicinal chemistry. The compound is a derivative of piperidine, containing a 4-ethylamino substituent and a tert-butoxycarbonyl (Boc) protecting group. 1-Boc-4-Ethylaminopiperidine is a versatile building block for the synthesis of various pharmaceuticals and bioactive compounds. It is also known for its potential as a precursor to drugs and research chemicals. 1-Boc-4-Ethylaminopiperidine has been widely studied for its potential pharmacological activities, such as its anticonvulsant and analgesic properties.

InChI:InChI=1/C12H24N2O2/c1-5-13-10-6-8-14(9-7-10)11(15)16-12(2,3)4/h10,13H,5-9H2,1-4H3

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 75-07-0 acetaldehyde 
• 75-04-7 ethylamine 
• 324769-06-4 tert-butyl 3,3-dimethyl-4-oxopiperidine-1-carboxylate 

Downstream Products

• 1152315-18-8 N-ethyl-2-phenyl-N-(piperidin-4-yl)acetamide 
• 1009633-55-9 C₂₀H₂₈ClN₃O₂ 
• 264903-99-3 2-(5-Amino-4-chloro-2-methoxyphenoxy)-N-ethyl-N-(4-piperidinyl)acetamide 
• 264903-98-2 2-(5-Amino-2-methoxyphenoxy)-N-ethyl-N-(4-piperidinyl)acetamide 
• 264904-06-5 2-(4-Amino-2,3,5-trimethylphenoxy)-N-ethyl-N-(4-piperidinyl)propamide 
• 264904-09-8 2-(4-Amino-2,3,5,6-tetramethylanilino)-N-ethyl-N-(4-piperidinyl)acetamide 
• 333987-42-1 1-tert-Butoxycarbonyl-4-{ethyl[4-(methylsulfanyl)phenylsulfonyl]amino}piperidine 
• 301232-31-5 4-(N-((2-chloro-4-fluorobenzyl)carbonyl)-N-ethylamino)piperidine trifluoroacetate 
• 301232-42-8 4-(N-((3,4-difluorobenzyl)carbonyl)-N-ethylamino)piperidine trifluoroacetate 
• 696644-12-9 C₃₆H₄₈F₆N₄O₃ 

Relevant articles and documents

Conjugate Addition of Perfluoroarenes to α,β-Unsaturated Carbonyls Enabled by an Alkoxide-Hydrosilane System: Implication of a Radical Pathway

Conjugate addition of organometallic reagents to α,β-unsaturated carbonyls is a key strategy for the construction of carbon-carbon bond in organic synthesis. Although direct C-H addition to unsaturated bonds via transition metal catalysis is explored in recent years, electron-deficient arenes that do not bear directing groups continue to be challenging. Herein we disclose the first example of a conjugate addition of perfluoroarenes to α,β-unsaturated carbonyls enabled by an alkoxide-hydrosilane system. The reaction is convenient to carry out at room temperature over a broad range of substrates and reactants to furnish synthetically versatile products in high to excellent yields. Mechanistic experiments in combination with computational studies suggest that a radical pathway is most likely operative in this transformation. The hypervalent silicate and silanide species, which are relevant to the proposed mechanism, were observed experimentally by NMR and single crystal X-ray diffraction analyses.

MUSCARINIC AGONISTS

This invention relates to compounds that are agonists of the muscarinic receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula (1a) or a salt thereof, wherein p, q, r, s, Q, R3 and R4 are as defined herein.

CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.